Journal Mobile Options
Table of Contents
Vol. 16, Suppl. 1, 2007
Issue release date: August 2007
Section title: Review

Open Access Gateway

Med Princ Pract 2007;16:10–15
(DOI:10.1159/000104541)

Principles of Pediatric Pain Management during the End-of-Life Period

Friedrichsdorf S.J.a · Collins J.J.b
aPain and Palliative Care Program, Children’s Hospitals and Clinics of Minnesota, Minneapolis, Minn., USA; bPain and Palliative Care Service, Children’s Hospital at Westmead, Sydney, Australia
email Corresponding Author

Stefan J. Friedrichsdorf, MD

Pain and Palliative Care Program, Children’s Hospitals and Clinics of Minnesota

2525 Chicago Avenue South, Minneapolis, MN 55404 (USA)

Tel. +1 612 813 6246, Fax +1 612 813 6358

E-Mail stefan.friedrichsdorf@childrensmn.org

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Abstract

More than 80% of children with a life-limiting condition such as cancer or a neurodegenerative disease suffer from pain during their last week of life. This article reviews the principles of pediatric pain management and addresses characteristics and pitfalls of integrative and pharmacological therapies during the end-of-life period of a child.Providing a good pain management for a dying child is one of the many domains of pediatric palliative care and usually requires a holistic, multidisciplinary approach and the knowledge to apply appropriate analgesic drugs in combination with integrative nondrug therapies.

© 2007 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Review

Received: 6/29/2005
Accepted: 4/2/2006
Published online: 8/17/2007
Issue release date: August 2007

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 1

ISSN: 1011-7571 (Print)
eISSN: 1423-0151 (Online)

For additional information: http://www.karger.com/MPP


Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.